| Biomarker ID | 1426 |
| PMID | 24803095 |
| Year | 2014 |
| Biomarker | PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Proteins Involved in Prostate Cancer |
| Experiment | Negative Vs Positive Biopsy for PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 122 patients who underwent pro tate biopsy because of PSA serum levels higher than 4.0 μg/L (93 with positive and 29 with negative biopsy) |
| Senstivity | 92.5% |
| Specificity | 41.4% |
| AUC | All Patients: 0.804; tPSA 4–10 μg/L: 0.793; tPSA 10.1–20 μg/L: 0.821; |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | The PCA3 score (the measurement of PCA3 mRNA normalized by PSA mRNA). The PCA3 score was calculated as 1/(ctPCA3/ctPSA) |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |